Focus Financial Network Inc. Has $1.25 Million Stake in Pfizer Inc. (NYSE:PFE)

Focus Financial Network Inc. lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 9.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,915 shares of the biopharmaceutical company’s stock after selling 5,068 shares during the quarter. Focus Financial Network Inc.’s holdings in Pfizer were worth $1,245,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC bought a new position in shares of Pfizer in the fourth quarter worth $26,000. Gladius Capital Management LP grew its stake in Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 38,015 shares in the last quarter. Teachers Insurance & Annuity Association of America acquired a new stake in Pfizer during the third quarter worth about $35,000. Joseph Group Capital Management increased its holdings in Pfizer by 168.3% in the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 771 shares during the period. Finally, Sugar Maple Asset Management LLC acquired a new position in shares of Pfizer in the 4th quarter valued at approximately $43,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of several analyst reports. Bank of America reiterated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Sanford C. Bernstein assumed coverage on Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target on the stock. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Citigroup decreased their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Finally, UBS Group dropped their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Trading Down 1.3 %

Shares of NYSE PFE opened at $25.53 on Wednesday. The firm has a 50 day moving average price of $26.28 and a two-hundred day moving average price of $27.69. The stock has a market cap of $144.69 billion, a P/E ratio of 18.11, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.10 earnings per share. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.74%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s payout ratio is currently 121.99%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.